Cath Lab

The catheterization lab channel includes content related to interventional technologies for coronary and peripheral artery disease (PAD). Other cath lab transcatheter device technologies covered on this page included percutaneous treatment for stroke, venous interventions, heart valves, hypertension, heart failure and percutenous coronary interventions (PCI).

News | FFR Technologies | Dave Fornell, Editor

October 22, 2020 – In the FORECAST randomized clinical trial, the use of fractional flow reserve (FFR) derived from ...

Home October 22, 2020
Home
Ori Ben-Yehuda, M.D., presenting the findings of the HOST-REDUCE-POLYTECH-ACS  study at TCT 2020 that showed durable polymer drug-eluting stents (DES) performed better than the bioresorbable polymer DES that were supposed to replace them with the promise of being safer and lowering overall cardiac event rates. #TCT2020 #TCTConnect
Feature | Stents | Dave Fornell, Editor

October 17, 2020 – In a surprise to many, a randomized clinical trial found that drug-eluting stents (DES) with durable ...

Home October 22, 2020
Home
News | Stents

October 22, 2020 – For patients undergoing percutaneous coronary intervention (PCI), treatment with the nanotechnology ...

Home October 22, 2020
Home
Videos | Coronavirus (COVID-19)

Chuck Simonton, M.D., chief medical officer at Abiomed, explains when advanced hemodynamic support is required in COVID ...

Home October 20, 2020
Home
Videos | Hemodynamic Support Devices

Chuck Simonton, M.D., chief medical officer at Abiomed, discusses some of the new technologies and clinical trials the ...

Home October 20, 2020
Home
Videos | Cath Lab

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
Videos | Stents Drug Eluting

Dean Kereiakes, M.D., medical director, The Christ Hospital Heart and Vascular Center, medical director, The Christ ...

Home October 19, 2020
Home
Videos | Antiplatelet and Anticoagulation Therapies

The COMPARE CRUSH Trial looked at the effect of per-hospital crushed prasugrel tablets in patients with STEMI planned ...

Home October 19, 2020
Home
Videos | Heart Valve Technology

Doctor Hans-Josef Feistritzerm, Heart Center of Leipzig, Germany, presents data on the use of general vs. local ...

Home October 19, 2020
Home
A large subgroup analysis of the VOYAGER PAD randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease (PAD). The study also found that the benefit of rivaroxaban use on reducing ischemic limb and cardiovascular outcomes was consistent regardless of whether a DCD was used. #TCT2020 #TCTconnect
Feature | Cath Lab

October 18, 2020 – A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit ...

Home October 18, 2020
Home
News | Drug-Eluting Balloons

October 18, 2020 – The first results from the IN.PACT Below the Knee (BTK) Study, a feasibility study assessing the ...

Home October 18, 2020
Home
News | Cath Lab

October 18, 2020 – Data from the COMBINE (OCT-FFR) study found that the use of FFR combined with OCT imaging can help ...

Home October 18, 2020
Home
News | Intravascular Imaging

October 18, 2020 – New data from the PROSPECT II study shows that near-infrared spectroscopy (NIRS) intravascular ...

Home October 18, 2020
Home
Subscribe Now